🔗 Visit the ClinicalTrials.gov page for NCT00518895
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. | J Clin Oncol | 2006 | 7.33 |
| 2 | Systematic review of medical treatment in melanoma: current status and future prospects. | Oncologist | 2011 | 2.89 |
| 3 | A melanoma molecular disease model. | PLoS One | 2011 | 1.15 |
| 4 | Interface of signal transduction inhibition and immunotherapy in melanoma. | Cancer J | 2010 | 0.77 |